ReportsnReports added Exosome Technologies Market Research Report created by Report Consultant, which offers detailed insights, revenue details, and other information regarding the global market, and the various trends, drivers, restraints, opportunities, and market till 2028. Exosome Technologies Market Report offers detailed information regarding the leading key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions and mergers, and market footprint. Exosome Technologies Market also provides a comparative analysis of the market dynamics pre and post Covid19 outbreak.
Request for FREE PDF Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=1781607
Exosome Technologies Market Report explores the application of exosome technologies within the pharmaceutical and healthcare industries. Exosomes are small cell-derived vesicles that are abundant in bodily fluids, including blood, urine and cerebrospinal fluid as well as in in vitro cell culture.
These vesicles are being used in a variety of therapeutic applications, including as therapeutic biomarkers, drug delivery systems and therapies in their own right. Research within this area remains in the nascent stages, although a number of clinical trials have been registered within the field. Exosomes have several diverse therapeutic applications, largely centering on stem cell and gene therapy. Exosomes have been identified as endogenous carriers of RNA within the body, allowing for the intercellular transportation of genetic material to target cells.
As such, developers have worked to engineer exosomes for the delivery of therapeutic miRNA and siRNA-based gene therapies. As RNA is highly unstable within the body, a number of different biologic vector systems have been developed to enhance their transport within the circulation, including viruses and liposomes. Similarly, exosomes derived from stem cells have also been identified for their therapeutic applications, particularly in the treatment of cancer and cardiovascular disease. Exosome technologies offer several advantages over existing biologic-based drug delivery systems.
They have a long circulatory half-life as a result of their high stability and ability to avoid breakdown by the mononuclear phagocyte system and reticuloendothelial systems. Moreover, exosomes have several functional properties that favor their use in therapeutic delivery. Exosomes can be engineered to incorporate targeting ligands, allowing them to deliver cargo selectively to cells. Their small size allows them to penetrate the blood-brain barrier for the delivery of central nervous system therapies, whereas in cancer they can accumulate within the tumor via enhanced permeability and retention effects.
Finally, clinical trials have shown relatively large-scale production to be possible and indicate that exosome therapies can be safely administered to humans. Additionally, exosomes are being investigated for their potential as prognostic and diagnostic biomarkers for several different disease indications. Exosomes make good candidates for biomarker research because of two unique characteristics: their presence in various accessible bodily fluids, and their resemblance to their parent cells of origin. R&D in exosome technologies has increased markedly in recent years. This report provides detailed information on the various healthcare applications of exosomes, and assesses the pipeline, clinical trial and company landscapes.
Scope of this Report-
- What are the features of the exosome lifecycle?
- How are therapeutic exosomes prepared?
- How do exosome therapies in development differ in terms of stage of development, molecule type and therapy area?
- Which companies are investing in exosome technologies?
- How many clinical trials investigate exosomes as biomarkers, therapeutics and vectors?
Reasons to buy this Report-
- Develop a comprehensive understanding of exosome technologies and their potential for use within the healthcare sector.
- Analyze the pipeline landscape and gain insight into the key companies investing in exosomes technologies.
- Identify trends in interventional and observational clinical trials relevant to exosomes.”
Single User License: US $ 2995
Get FLAT 20% Discount on this Report @ https://www.reportsnreports.com/purchase.aspx?name=1781607
Table of Contents in this Report-
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Exosomes in Healthcare 8
2.1 Overview of Exosomes 8
2.2 Drug Delivery Systems 9
2.2.1 Modified Release Drug Delivery Systems 9
2.2.2 Targeted Drug Delivery Systems 10
2.2.3 Liposomes 12
2.2.4 Viruses 14
2.2.5 Exosomes 17
2.3 The Exosome Lifecycle 18
2.4 Exosomes in Biology 18
2.5 Exosomes in Medicine 19
2.5.1 Biomarkers 19
2.5.2 Vaccines 20
2.6 Exosomes as a Therapeutic Target 20
2.7 Exosomes as Drug Delivery Vehicles 21
2.8 Therapeutic Preparation of Exosomes 21
2.8.1 Isolation and Purification 22
2.8.2 Drug Loading 22
2.8.3 Characterization 23
2.8.4 Bioengineering 23
2.8.5 Biodistribution and In Vivo Studies 23
2.8.6 Advantages of Exosome Therapies 24
2.8.7 Disadvantages of Exosome Therapies 24
2.9 Exosomes in Therapeutic Research 25
2.9.1 Exosome Gene Therapies 25
2.9.2 Exosome in Stem Cell Therapy 26
2.10 Exosomes in Oncology 27
2.10.1 Immunotherapy 27
2.10.2 Gene Therapy 28
2.10.3 Drug Delivery 29
2.10.4 Biomarkers 30
2.11 Exosomes in CNS Disease 30
2.11.1 Tackling the Blood-Brain Barrier 30
2.11.2 Exosomes in CNS Drug Delivery 31
2.11.3 Gene Therapy 32
2.12 Exosomes in Other Diseases 33
2.12.1 Cardiovascular Disease 33
2.12.2 Metabolic Disease 33
3 Assessment of Pipeline Product Innovation 36
3.1 Overview 36
3.2 Exosome Pipeline by Stage of Development and Molecule Type 36
3.3 Pipeline by Molecular Target 37
3.4 Pipeline by Therapy Area and Indication 38
3.5 Pipeline Product Profiles 38
3.5.1 AB-126 – ArunA Biomedical Inc. 38
3.5.2 ALX-029 and ALX-102 – Alxerion Biotech 39
3.5.3 Biologics for Autism – Stem Cell Medicine Ltd 39
3.5.4 Biologic for Breast Cancer – Exovita Biosciences Inc. 39
3.5.5 Biologics for Idiopathic Pulmonary Fibrosis and Non-alcoholic Steatohepatitis – Regenasome Pty 39
3.5.6 Biologic for Lysosomal Storage Disorder – Exerkine 39
3.5.7 Biologics for Prostate Cancer – Cells for Cells 40
3.5.8 CAP-2003 – Capricor Therapeutics Inc. 40
3.5.9 CAP-1002 – Capricor Therapeutics Inc. 41
3.5.10 CIL-15001 and CIL-15002 – Ciloa 42
3.5.11 ExoPr0 – ReNeuron Group Plc 42
3.5.12 MVAX-001 – MolecuVax Inc. 43
3.5.13 Oligonucleotides to Activate miR124 for Acute Ischemic Stroke – Isfahan University of Medical Sciences 44
3.5.14 Oligonucleotides to Inhibit KRAS for Pancreatic Cancer – Codiak BioSciences Inc. 44
3.5.15 Proteins for Neurology and Proteins for CNS Disorders and Oligonucleotides for Neurology – Evox Therapeutics Ltd 44
3.5.16 TVC-201 and TVC-300 – Tavec Inc. 45
4 Assessment of Clinical Trial Landscape 48
4.1 Interventional Clinical Trials 48
4.1.1 Clinical Trials by Therapy Type 48
4.1.2 Clinical Trials by Therapy Area 49
4.1.3 Clinical Trials by Stage of Development 50
4.1.4 Clinical Trials by Start Date and Status 50
4.2 Observational Clinical Trials 51
4.2.1 Clinical Trials by Therapy Type 51
4.2.2 Clinical Trials by Therapy Area 51
4.2.3 Clinical Trials by Stage of Development 52
4.2.4 Clinical Trials by Start Date and Status 53
4.2.5 List of All Clinical Trials 54
and more..
